NCT07070778 Arterial Stiffness in Individuals With Breast Cancer
| NCT ID | NCT07070778 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hacettepe University |
| Condition | Aerobic Exercise |
| Study Type | INTERVENTIONAL |
| Enrollment | 18 participants |
| Start Date | 2025-07-08 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 18 participants in total. It began in 2025-07-08 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study was to evaluate vascular toxicity induced by anthracyclines and other anticancer drugs and to measure arterial stiffness in women with breast cancer and, in addition, to evaluate the acute and chronic arterial stiffness responses of upper extremity aerobic exercise training.
Eligibility Criteria
Inclusion Criteria: * To be between the ages of 40-69, * Baseline left ventricular ejection fraction (LVEF) \>50%, * Absence of coronary artery disease and haemodynamically significant valvular heart disease, * Absence of carotid atherosclerotic plaques, * Volunteering to participate in the research, * At least 15 months after breast cancer surgery, * No problems in reading and/or understanding the scales and being able to co-operate with the tests. * Physically inactive (60 minutes of structured exercise per week \<). Exclusion Criteria: * Presence of active infection, * Presence of bilateral breast cancer, * History of surgical, neurological or orthopaedic problems that may affect upper extremity functionality other than breast cancer surgery, * Having a neurological disease or other clinical diagnosis that may affect cognitive status, * Left ventricular dysfunction and severe liver and kidney dysfunction before starting chemotherapy * Musculoskeletal and neurological disease that may affect exercise performance, symptomatic heart disease, previous lung surgery and malignant disease. * Presence of unstable hypertension or diabetes mellitus.
Contact & Investigator
Melda Saglam, PhD
STUDY CHAIR
Hacettepe University
Frequently Asked Questions
Who can join the NCT07070778 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 69 Years, studying Aerobic Exercise. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07070778 currently recruiting?
Yes, NCT07070778 is actively recruiting participants. Contact the research team at ebru.calik@hacettepe.edu.tr for enrollment information.
Where is the NCT07070778 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07070778 clinical trial?
NCT07070778 is sponsored by Hacettepe University. The principal investigator is Melda Saglam, PhD at Hacettepe University. The trial plans to enroll 18 participants.